Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RENOTORCH: Toripalimab + Axitinib in Advanced RCC
NCT04394975Phase 3Completed
- Sponsor
- Shanghai Junshi Biosciences Co., Ltd.
- Start
- Aug 2020
- Primary completion
- Apr 2024
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of toripalimab in renal cell carcinoma (RCC), sponsored by Shanghai Junshi Biosciences Co., Ltd.. Started Aug 2020; status: completed.
02
Drugs
toripalimab
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT04394975.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04394975.